Table 3—

Clinical and metabolic characteristics of 18 high-risk African Americans who progressed to IGT and/or type 2 diabetes and 19 healthy subjects who did not progress at the end of 8 years

ParametersNonprogressors
Progressors GIT
P value
BaselineAfter 6 yearsBaselineAfter 6 yearsNonprogressors: baseline vs. after 6 yearsProgressors vs. nonprogressors: baselineProgressors vs. nonprogressors: after 6 years
n19191818
Age (years)42.1 ± 8.249.1 ± 7.945.4 8.251.6 8.50.011NSNS
Sex ratio (female/male)16/316/314/1414/4
Body weight (kg)84.7 ± 0.785.0 ± 3.098.7 ± 19103.6 ± 20.9NSNS0.073
Height (m)1.64 ± 0.71.61 ± 0.71.66 ± 0.91.65 ± 0.1NSNSNS
BMI (kg/m2)33.5 ± 7.032.4 ± 6.735.4 ± 5.937.7 ± 6.4NSNS0.030
Waist-to-hip ratio0.88 ± 0.060.88 ± 0.050.91 ± 1.100.93 ± 0.370.04NSNS
Systolic blood pressure (mmHg)126.6 ± 20.0129.1 ± 14.7127 ± 14138 ± 20NSNSNS
Diastolic blood pressure (mmHg)81.2 ± 14.182.8 ± 11.778 ± 1282 ± 12NSNSNS
Lipids and lipoproteins (mg/dl)
 Cholesterol195 ± 32191 ± 26205 ± 31235 ± 40NSNS0.001
 Triglycerides82 ± 3077 ± 32128 ± 4184 ± 60NS0.0010.001
 HDL cholesterol57.9 ± 13.751.4 ± 12.344.5 ± 10.141.7 ± 11.7NS0.0860.001
 LDL cholesterol150 ± 49124 ± 22135 ± 3140 ± 53NSNSNS
  • Data are means ± SD. Progressors GIT (glucose intolerance) represents patients in both the IGT and diabetes groups who progressed during the 5–8 years of follow-up.